EGFR is a transducer of the urokinase receptor initiated signal that is required for in vivo growth of a human carcinoma

Cancer Cell

Volumn 1, Issue 5, 2002, Pages 445-457

  Liu, David ^a   Aguirre Ghiso, Julio A ^a   Estrada, Yeriel ^a   Ossowski, Liliana ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; FIBRONECTIN; INTEGRIN; UROKINASE RECEPTOR; 4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; BETA1 INTEGRIN; CELL SURFACE RECEPTOR; ENZYME INHIBITOR; FIBRONECTIN RECEPTOR; FOCAL ADHESION KINASE; FOCAL ADHESION KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE; PLASMINOGEN ACTIVATOR, UROKINASE RECEPTORS; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE PHOSPHATASE; PTK2 PROTEIN, HUMAN; TYRPHOSTIN;

ARTICLE; CANCER CELL; CANCER GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME ACTIVATION; GENE ACTIVITY; GENE CONTROL; GENE EXPRESSION; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; LIGAND BINDING; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; CELL CULTURE; CELL DIVISION; DRUG ANTAGONISM; LIVER CELL CARCINOMA; LIVER TUMOR; METABOLISM; NORTHERN BLOTTING; PATHOLOGY; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANTIGENS, CD29; BLOTTING, NORTHERN; CARCINOMA, HEPATOCELLULAR; CELL DIVISION; ENZYME ACTIVATION; ENZYME INHIBITORS; FOCAL ADHESION KINASE 1; FOCAL ADHESION PROTEIN-TYROSINE KINASES; HUMANS; LIVER NEOPLASMS; MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN-TYROSINE KINASES; PROTEIN-TYROSINE-PHOSPHATASE; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, CELL SURFACE; RECEPTORS, FIBRONECTIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED; TYRPHOSTINS;

EID: 0036596352     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1535-6108(02)00072-7     Document Type: Article

References (37)

1. Aguirre Ghiso, J.A. (2002). Inhibition of FAK signaling activated by urokinase receptor induces dormancy in human carcinoma cells in vivo. Oncogene 21, 2513-2524.
2. Aguirre Ghiso, J.A., Kovalski, K., and Ossowski, L. (1999). Tumor dormancy induced by down regulation of urokinase receptor in human carcinoma involves integrin and MARK signaling. J. Cell Biol. 147, 89-104.
3. Aguirre Ghiso, J.A., Liu, D., Mignatti, A., Kovalski, K., and Ossowski, L. (2001). Urokinase receptor and fibronectin regulate the ERK(MAPK) to p38(MAPK) activity ratios that determine carcinoma cell proliferation or dormancy in vivo. Mol. Biol. Cell 12, 863-879.
4. Andreasen, P.A., Kjøller, L., Christensen, L., and Duffy, M.J. (1997). The urokinase-type plasminogen activator system in cancer metastasis: a review. Int. J. Cancer 72, 1-22.
5. Bazzoni, G., Shih, D.T., Buck, C.A., and Hemler, M.E. (1995). Monoclonal antibody 9EG7 defines a novel beta 1 integrin epitope induced by soluble ligand and manganese, but inhibited by calcium. J. Biol. Chem. 270, 25570-25577.
6. Bazzoni, G., Ma, L., Blue, M.L., and Hemler, M.E. (1998). Divalent cations and ligands induce conformational changes that are highly divergent among betal integrins. J. Biol. Chem. 273, 6670-6678.
7. Bissell, M.J., Weaver, V.M., Lelievre, S.A., Wang, F., Petersen, O.W., and Schmeichel, K.L. (1999). Tissue structure, nuclear organization, and gene expression in normal and malignant breast. Cancer Res. 59, 1757-1763.
8. Cary, L.A., and Guan, J.L. (1999). Focal adhesion kinase in integrin-mediated signaling. Front. Biosci. 4, D102-D113.
9. Daub, H., Weiss, F.U., Wallasch, C., and Ullrich, A. (1996). Role of transactivation of the EGF receptor in signalling by G-protein- coupled receptors. Nature 379, 557-560.
10. Diaz-Gonzalez, F., Forsyth, J., Steiner, B., and Ginsberg, M.H. (1996). Transdominant inhibition of integrin function. Mol. Biol. Cell 7, 1939-1951.
11. Giancotti, F.G., and Ruoslahti, E. (1999). Integrin signaling. Science 285, 1028-1032.
12. Goishi, K., Higashiyama, S., Klagsbrun, M., Nakano, N., Umata, T., Ishikawa, M., Mekada, E., and Taniguchi, N. (1995). Phorbol ester induces the rapid processing of cell surface heparin-binding EGF-like growth factor: conversion from juxtacrine to paracrine growth factor activity. Mol. Biol. Cell 6, 967-980.
13. Hemler, M.E. (1998). Integrin associated proteins. Curr. Opin. Cell Biol. 10, 578-585.
14. Hodivala-Dilke, K.M., DiPersio, C.M., Kreidberg, J.A., and Hynes, R.O. (1998). Novel roles for alpha3beta1 integrin as a regulator of cytoskeletal assembly and as a trans-dominant inhibitor of integrin receptor function in mouse keratinocytes. J. Cell Biol. 142, 1357-1369.
15. Hoyer-Hansen, G., Ronne, E., Solberg, H., Behrendt, N., Ploug, M., Lund, L.R., Ellis, V., and Dano, K. (1992). Urokinase plasminogen activator cleaves its cell surface receptor releasing the ligand-binding domain. J. Biol. Chem. 267, 18224-18229.
16. Keely, P., Parise, L., and Juliano, R. (1998). Integrins and GTPases in tumour cell growth, motility and invasion. Trends Cell Biol. 8, 101-106.
17. Kook, Y.H., Adamski, J., Zelent, A., and Ossowski, L. (1994). The effect of antisense inhibition of urokinase receptor in human squamous cell carcinoma on malignancy. EMBO J. 13, 3983-3991.
18. Kuwada, S.K., and Li, X. (2000). Integrin alpha5/beta1 mediates fibronectin-dependent epithelial cell proliferation through epidermal growth factor receptor activation. Mol. Biol. Cell 11, 2485-2496.
19. May, A.E., Neumann, F.J., Schomig, A., and Preissner, K.T. (2000). VLA-4 (alpha4/beta1) engagement defines a novel activation pathway for beta2 integrin-dependent leukocyte adhesion involving the urokinase receptor. Blood 96, 506-513.
20. Mitamura, T., Higashiyama, S., Taniguchi, N., Klagsbrun, M., and Mekada, E. (1995). Diphtheria toxin binds to the epidermal growth factor (EGF)-like domain of human heparin-binding EGF-like growth factor/diphtheria toxin receptor and inhibits specifically its mitogenic activity. J. Biol. Chem. 270, 1015-1019.
21. Miyamoto, S., Teramoto, H., Gutkind, J.S., and Yamada, K.M. (1996). Integrins can collaborate with growth factors for phosphorylation of receptor tyrosine kinases and MAP kinase activation: roles of integrin aggregation and occupancy of receptors. J. Cell Biol. 135, 1633-1642.
22. Montuori, N., Rossi, G., and Ragno, P. (1999). Cleavage of urokinase receptor regulates its interaction with integrins in thyroid cells. FEBS Lett. 460, 32-36.
23. Moro, L., Venturino, M., Bozzo, C., Silengo, L., Altruda, F., Beguinot, L., Tarone, G., and Defilippi, P. (1998). Integrins induce activation of EGF receptor: role in MAP kinase induction and adhesion-dependent cell survival. EMBO J. 17, 6622-6632.
24. Nicholson, R.I., Gee, J.M., and Harper, M.E. (2001). EGFR and cancer prognosis. Eur. J. Cancer 37 (Suppl 4), S9-S15.
25. Ossowski, L., and Aguirre Ghiso, J.A. (2000). Urokinase receptor and integrin partnership: coordination of signaling for cell adhesion, migration and growth. Curr. Opin. Cell Biol. 12, 613-620.
26. Ossowski, L., and Reich, E. (1980). Loss of malignancy during serial passage of human carcinoma in culture and discordance between malignancy and transformation parameters. Cancer Res. 40, 2310-2315.
27. Redemann, N., Holzmann, B., von Ruden, T., Wagner, E.F., Schlessinger, J., and Ullrich, A. (1992). Anti-oncogenic activity of signalling-defective epidermal growth factor receptor mutants. Mol. Cell. Biol. 12, 491-498.
28. Ruoslahti, E. (1999). Fibronectin and its integrin receptors in cancer. Adv. Cancer Res. 76, 1-20.
29. Schlessinger, J. (2000). Cell signaling by receptor tyrosine kinases. Cell 103, 211-225.
30. Schmitt, M., Wilhelm, O.G., Reuning, U., Kruger, A., Harbeck, N., Lengyel, E., Graeff, H., Gansbacher, B., Kessler, H., Burgle, M., et al. (2000). The urokinase plasminogen activator system as a novel target for tumor therapy. Fibrinolysis Proteolysis 14, 114-132.
31. Sieg, D.J., Hauck, C.R., Ilic, D., Klingbeil, C.K., Schaefer, E., Damsky, C.H., and Schlaepfer, D.D. (2000). FAK integrates growth-factor and integrin signals to promote cell migration. Nat. Cell Biol. 2, 249-256.
32. Spivak-Kroizman, T., Rotin, D., Pinchasi, D., Ullrich, A., Schlessinger, J., and Lax, I. (1992). Heterodimerization of c-erbB2 with different epidermal growth factor receptor mutants elicits stimulatory or inhibitory responses. J. Biol. Chem. 267, 8056-8063.
33. Todd, R.F., 3rd, and Petty, H.R. (1997). Beta 2 (CD11/CD18) integrins can serve as signaling partners for other leukocyte receptors. J. Lab. Clin. Med. 129, 492-498.
34. Toolan, H.W. (1954). Transplantable human neoplasms maintained in cortisone-treated laboratory animals: HS#1, H.Ep#1, H.Ep.#2, H.Ep.#3, and H.Emb.#1. Cancer Res. 14, 660-666.
35. Ullrich, A., Coussens, L., Hayflick, J.S., Dull, T.J., Gray, A., Tam, A.W., Lee, J., Yarden, Y., Libermann, T.A., Schlessinger, J., et al. (1984). Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature 309, 418-425.
36. Wary, K.K., Mariotti, A., Zurzolo, C., and Giancotti, F.G. (1998). A requirement for caveolin-1 and associated kinase Fyn in integrin signaling and anchorage-dependent cell growth. Cell 94, 625-634.
37. Yu, W., Kim, J., and Ossowski, L. (1997). Reduction in surface urokinase receptor forces malignant cells into a protracted state of dormancy. J. Cell Biol. 137, 767-777.